MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Heron Therapeutics Inc

Fechado

SetorSaúde

1.49

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.45

Máximo

1.51

Indicadores-chave

By Trading Economics

Rendimento

-15M

-17M

Vendas

1M

38M

Margem de lucro

-45.783

Funcionários

122

EBITDA

-12M

-14M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+202.01% upside

Dividendos

By Dow Jones

Próximos Ganhos

26 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

57M

273M

Abertura anterior

1.49

Fecho anterior

1.49

Sentimento de Notícias

By Acuity

37%

63%

118 / 361 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Heron Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de jan. de 2026, 23:29 UTC

Ações em Alta

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 de jan. de 2026, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 de jan. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 de jan. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Auto & Transport Roundup: Market Talk

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

16 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

16 de jan. de 2026, 21:48 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 de jan. de 2026, 21:41 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 de jan. de 2026, 21:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 de jan. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 de jan. de 2026, 20:44 UTC

Ganhos

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 de jan. de 2026, 20:42 UTC

Conversa de Mercado

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 de jan. de 2026, 20:28 UTC

Conversa de Mercado

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 de jan. de 2026, 19:12 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 de jan. de 2026, 18:53 UTC

Conversa de Mercado

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 de jan. de 2026, 18:41 UTC

Conversa de Mercado

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 de jan. de 2026, 18:31 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 de jan. de 2026, 17:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

16 de jan. de 2026, 17:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

16 de jan. de 2026, 17:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

16 de jan. de 2026, 17:03 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

16 de jan. de 2026, 17:03 UTC

Conversa de Mercado

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 de jan. de 2026, 16:32 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 de jan. de 2026, 16:20 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Heron Therapeutics Inc Previsão

Preço-alvo

By TipRanks

202.01% parte superior

Previsão para 12 meses

Média 4.5 USD  202.01%

Máximo 6 USD

Mínimo 3 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Heron Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

4

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.0001 / 2.42Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

118 / 361 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat